An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

NCT02737475 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: BMS-986178
DRUG: Nivolumab
DRUG: Ipilimumab
BIOLOGICAL: Tetanus vaccine
BIOLOGICAL: DPV-001 vaccine
DRUG: Cyclophosphamide

Sponsor

Bristol-Myers Squibb